Institute of Immunology, Rikshospitalet, University of Oslo, Oslo, Norway.
Autoimmun Rev. 2010 Apr;9(6):459-64. doi: 10.1016/j.autrev.2009.12.011. Epub 2010 Jan 1.
Extracorporeal photochemotherapy, or photopheresis is a low-risk therapeutical intervention, which has been introduced in a variety of hematological malignancies, autoimmune conditions and transplantation. The mode of action of photopheresis encompasses apoptosis-induction and modifications of immunoregulatory processes, leading to the elimination of malignant cells, as well as the down-modulation of harmful immune responses. Although the beneficial effects of the therapy have been depicted in numerous studies, little is known about the exact benefits and the molecular mechanisms behind. The aim of the present review was to portray some aspects of the molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation, and to provide an overview of the treatment in the modern clinical management of these diseases.
体外光化学疗法，或光分离术是一种低风险的治疗干预措施，已被应用于多种血液系统恶性肿瘤、自身免疫性疾病和移植中。光分离术的作用模式包括诱导细胞凋亡和调节免疫调节过程，从而消除恶性细胞，并下调有害的免疫反应。尽管许多研究已经描述了该疗法的有益效果，但对于其确切的益处和分子机制知之甚少。本综述的目的是描述体外光化学疗法在自身免疫性疾病、恶性肿瘤和移植中的分子和临床原理的一些方面，并概述该疗法在这些疾病的现代临床管理中的应用。
